Nice find Donk, Your comments are well founded. Let me conjecture,additionally, that at some future time RGRX may apply for orphan drug status for EB. It's difficult to figure any time table but the Oct. TB-4 symposium is meaningful.
I think news on eye events is big. Look at what happened when NK was announced. Couple this NIH monies and fireworks go off. The market reacts before the actual clinical takes place, sometime during the 4thQ. New investors foresee a J&J connection and 4th Q selling becomes their buying opportunity. The stars are alined.
I believe the MM's control the trading.They receive the market orders and decide to sit on them or cross them.
My time frame is the 4thQ of 2014. Clinical trial eye updates are given along with possible neuro monies.
100,000 shares was on the bid side all day and the MM's crossed a meager amount making the commission high. It amounts to the MM's total control of trading and the price. It's Awful.
Someone bought about 250,000 shares at $4.40 in the last 5 min. of trading, yesterday. Nice! It could bode well for a positive opening on Mon. During the course of trading the past week a lot of shares crossed at the same price.
New indications using Thymosin Beta 4 (TB4) appear on a regular bases as shown in articles of Pub Med and elsewhere.Because the many indications cited, there is the temptation for RGRX to consider getting away from their expertise, heart and eye applications.
It would be a mistake to do so with the its limited cash assets. That doesn't mean that RGRX can not expand one of their areas of expertise, eye treatment. The Asian market for dry eye treatment is open and will be pursued. That's a given. Another wide open market in eye treatment is glaucoma and since the disease, in Asia, is caused by inflammation it would be natural to think of expanding into the treatment of glaucoma.
A drug has been found to activate latent (hidden) HIV. Researchers have discovered that the drug alone has to be combined with a vaccine to be effective. Matrix-M should be a candidate as the vaccine's adjuvant. Importantly, the drug, for the first time, exposes latent HIV virus to the immune system that could destroy and eliminate 100% of it. If successful a cure for the dreaded disease will have been found.
If the price keeps going up, and it has been all week, between now and the release of quarterly earnings, then one would think an important development will be announced. Time will tell.
We are in the right place,at the right time and in the right field.
Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn
Saudi Arabian researchers have detected genetic fragments of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the air of a barn holding a camel infected with the virus. The work, published this week in mBio®, the online open-access journal of the American Society for Microbiology, indicates that further studies are needed to see if the disease can be transmitted through the air.
MERS, a serious viral respiratory illness caused by the coronavirus, has been identified in 699 people as of June 11, according to the World Health Organization; 209 people have died from the condition. An additional 113 cases occurring between 2012 and 2014 were reported by the Saudi Arabian Ministry of Health on June 3.
For the study, researchers on three consecutive days last November collected three air samples from a camel barn owned by a 43-year-old male MERS patient who lived south of the town of Jeddah, who later died from the condition. Four of the man's nine camels had shown signs of nasal discharge the week before the patient became ill; he had applied a topical medicine in the nose of one of the ill camels seven days before experiencing symptoms.
Using a laboratory technique called reverse transcription polymerase chain reaction (RT-PCR) to detect gene expression, they found that the first air sample, collected on November 7, contained genetic fragments of MERS-CoV. This was the same day that one of the patient's camels tested positive for the disease. The other samples did not test positive for MERS-CoV, suggesting short or intermittent shedding of the virus into the air surrounding the camels, said lead study author Esam Azhar, PhD, head of the Special Infectious Agents Unit at King Fahd Medical Research Center and associate professor of medical virology at King Abdulaziz University in Jeddah.
Additional experiments confirmed the presence of MERS-CoV-specific genetic se
AHMEDABAD: On World Environment Day, Ahmedabad based Cadila Pharmaceuticals decided to launch a campaign to reduce the consumption of paper at its various premises.
As part of the campaign, the company took various initiatives including tree plantation, save paper campaign, quiz and drawing competitions at its premises in Bhat, Ankleshwar, Dholka and Hirapur in Ahmedabad on June 5.
"We firmly believe in preserving our environment and have taken various initiatives to make the world greener. Every year, we have been carrying out various awareness activities. year, we decided to make employees aware about reducing the consumption of paper in form of print outs and photocopies and urged them to be conservative when it comes to printing documents," said, Rajiv Modi, chairman and managing director, Cadila Pharmaceuticals.
Last year, employees of the company had taken a pledge to save water and power, plant more trees, stop using plastic bags and save paper. Through its Save Paper campaign- the company intends to drive home the point and motivate its employees to be conscious of the environment and print only if necessary.
I appears malaria research is heading in a new direction with the suppression of proteins being a new target. NVAX is doing research on malaria parasite proteins, but the specifics have never been made public. Given this, it's hard to evaluate if the research is of value. Novavax needs to be transparent.
Sorry, please insert the word percent in the last sentence. "About 50 (percent) of Asians who have elevated intraocular pressure,have this kind of glaucoma."
Additionally, the potential market is huge. A drug that reduces inflammation or eliminates, it such as TB4, would command the market. Most likely several treatments would be necessary. Our partner in Korea sees the opportunity and its a reason they're moving into the biotechnology space.
I wrote another post under the title"Another Market for TB4?" that shows that glaucoma could be relevant to both RGRX and g-tree BNT. The info can be viewed under the original title " Another Market for TB4?
Upon reading the patent application titled,"Method Of Achieving A Thymosin Beta 4 Concentration In a Human Patient" I noticed one of the claims made was for elevated intraocular pressure (glaucoma). The claim was listed separate from all other claims made.
I believe this indication is a part of the reason for the g-tree BNT investment in RGRX. It bears watching because parts of Asia including China have a problem with a particular kind of glaucoma called Acute closed Angle glaucoma. About 50 of Asians whose have elevated intraocular pressure have this kind of glaucoma.
The size of the market makes the difference and as sno pointed out J&J is looking for a large market opportunity.
Additionally JJ is expendable and will not have much say should J&J deem the drug opportunistic.
There are no problems with the results of the heart research according to the abstract and RGRX's release. J&J has to come to RGRX because of the issued patents. The fact that RGRX published the results is important and may signal talks between them and if that's the case a J&J RGRX deal is in the works. It appears the drug has a good chance to be successful in a new preclinical trial-a primate trial. The market potential is huge and I believe J&J will pursue this opportunity. Other areas of interest will follow and J&J and RGRX could have all the ducks in a row for an eventual buyout. I realize the commentary is inferential but possible.